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In patients with chronic hepatitis C, determination of hepatitis C virus (HCV) genotype could be routinely
run in the future to tailor treatment schedules. The suitabilities of two versions of a serological, so-called
serotyping assay (Murex HCV Serotyping Assay version 1-3 [SA1-3] and Murex HCV Serotyping Assay version
1-6 [SA1-6]; Murex Diagnostics Ltd.), based on the detection of genotype-specific antibodies directed to
epitopes encoded by the NS4 region of the genome, for the routine determination of HCV genotypes were
studied. The results were compared with those of a molecular biology-based genotyping method (HCV Line
Probe Assay [INNO-LiPA HCV]; Innogenetics S.A.), based on hybridization of PCR products onto genotype-
specific probes designed in the 5* noncoding region of the genome, obtained with pretreatment serum samples
from 88 patients with chronic hepatitis C eligible for interferon therapy. Definitive genotyping was performed
by sequence analysis of three regions of the viral genome in all samples with discrepant typing results found
among at least two of the three assays studied. In all instances, sequence analysis confirmed the result of the
INNO-LiPA HCV test. The sensitivity of SA1-3 was 75% relative to the results obtained by the genotyping assay.
The results were concordant with those of genotyping for 92% of the samples typeable by SA1-3. The sensitivity
of SA1-6 was 89% relative to the results obtained by the genotyping assay. The results were concordant with
those of genotyping for 94% of the samples typeable by SA1-6. Overall, SA1-6 had increased sensitivity relative
to SA1-3 but remained less sensitive than the genotyping assay on the basis of PCR amplification of HCV RNA.
Cross-reactivities between different HCV genotypes could be responsible for the mistyping of 8 (SA1-3) and 6%
(SA1-6) of the samples. Subtyping of 1a and 1b is still not possible with the existing peptides, but discrimi-
nating between subtypes may not be necessary for routine use.
Recently, sequences of different hepatitis C virus (HCV)
variants were classified into different genotypes on the basis of
overall sequence similarity (2, 20, 22, 24). HCV genotypes are
likely the result of spontaneous mutations that occurred in the
genome, that were selected in specific geographical areas, and
that could, later, spread widely owing to population mixing and
new routes of transmission. A consensus nomenclature for
HCV genotypes has been proposed (19), in which the six main
HCV types identified so far are numbered in the order of their
discovery, i.e., 1 to 6. Within each type, subtypes have been
identified by lowercase letters, which are also given in order of
discovery. Most of the HCV strains present in industrialized
countries are HCV genotype 1, 2, or 3 (6, 16).
HCV genotypes and subtypes seem to have important sig-
nificance in the epidemiology and pathogenesis of HCV-re-
lated disease. We recently observed that HCV genotypes were
significantly related to the source of infection (18). On the
other hand, HCV genotype 1b could be associated with more
severe liver disease than other types, as recently reported for
HCV-positive liver graft recipients (5). Finally, HCV genotype
1 seems to be associated with a worse response to interferon
alfa therapy in patients with chronic hepatitis C (7, 11, 16).
Whether the routine determination of HCV genotype could be
useful in the management of patients with chronic hepatitis C
remains unclear. With the refinement of interferon schedules
and the development of new antiviral molecules in the fore-
seeable future, tailoring of therapeutic schedules to various
pretreatment parameters, including HCV genotype, will prob-
ably be required.
Molecular biology-based genotyping methods have been
widely used for research purposes. However, they are time-
consuming and expensive, require specific molecular biology
equipment and experience, and are not adapted to large-scale
HCV genotype determination. This emphasizes the need for
more practicable typing technologies, and several investigators
have proposed serological techniques of HCV genotype deter-
mination (so-called serotyping techniques) based on the detec-
tion of genotype-specific antibodies by immunoenzymatic
methods (1, 4, 10, 21, 25, 26). In addition to their theoretically
better suitability than molecular biology-based methods for
routine use, serotyping methods could prove particularly useful
in determining the HCV genotype in HCV RNA-negative pa-
tients and in identifying infections with multiple genotypes.
Anti-HCV antibody reactivities have been shown to be in-
fluenced by HCV genotypes (8, 17). In particular, epitopes
encoded by the NS4 region of the HCV genome emerged as
candidates for discriminating serologically among patients in-
fected with different HCV genotypes (8, 17). A serotyping
assay based on the use of branched synthetic peptides and
* Corresponding author. Mailing address: Service de Bacte´riologie-
Virologie, Hoˆpital Henri Mondor, 51 avenue du Mare´chal de Lattre de
Tassigny, 94010 Creteil, France. Phone: (33) 1.49.81.28.31. Fax: (33)
1.49.81.28.39. E-mail: pawlotsky@univ-paris12.fr.
1734
competition enzyme-linked immunosorbent assay (ELISA) has
been developed to detect genotype-specific anti-NS4 antibod-
ies directed to HCV genotypes 1, 2, and 3 (21). This assay has
later been improved and commercialized in a standardized
format (Murex Anti-HCV Serotyping Assay version 1-3 [SA1-
3]; Murex Diagnostics Ltd., Dartford, United Kingdom). Re-
cently, a new version of this serotyping assay (Murex Anti-
HCV Serotyping Assay version 1-6 [SA16]) has been
developed; the new version included a larger number of
branched peptides to identify HCV genotypes 1 through 6 and
several technical modifications (1). Both versions of the assay
have been successfully used to determine HCV genotypes in
selected populations of HCV-positive patients or blood donors
(1, 21).
The aim of this study was to determine the suitability of the
two versions of this competitive ELISA-based serotyping assay
for routine determination of HCV genotype. For this, the
results of the two serotyping assays were compared with those
of a standardized molecular biology-based genotyping method
based on hybridization of PCR products onto genotype-spe-
cific probes designed in the 59 noncoding region of the ge-
nome. The study materials comprised pretreatment serum
samples from patients with chronic hepatitis C eligible for
interferon therapy, the main target group for the large-scale,
routine use of HCV genotype determination in the future.
MATERIALS AND METHODS
Patients. Eighty-eight consecutive patients with chronic hepatitis C (53 men
and 35 women; mean age, 46 years) eligible for interferon alfa therapy were
studied. The diagnosis of chronic hepatitis C was based on persistently elevated
serum alanine aminotransferase activity, chronic hepatitis on liver biopsy, and
the presence in serum of anti-HCV antibodies detected by third-generation
detection and confirmatory assays (Ortho Diagnostic Systems, Raritan, N.J.).
The patients were all negative for hepatitis B surface antigen and antibodies to
human immunodeficiency virus. Informed consent was obtained from each pa-
tient, and the study protocol conformed to ethical guidelines, as reflected by
approval by the institutions’ (Hoˆpital Henri Mondor, Cr´eteil, and Hoˆpital de
Biceˆtre, Le Kremlin-Biceˆtre) human research review committee. Serum samples
were aliquoted before any treatment, and aliquots were frozen at 280°C. The
HCV genotype was determined by means of the genotyping assay and the two
versions of the serotyping assay. When the results of the genotyping and the
serotyping assays were discrepant, the 59 noncoding, core, and NS4 regions of the
samples were amplified by PCR, and the PCR products were sequenced directly
and from clones (NS4) for definitive genotype determination.
Genotyping assay. The HCV Line Probe Assay (INNO-LiPA HCV; Innoge-
netics S.A., Ghent, Belgium) was used to determine HCV genotypes. For this
procedure, the highly conserved 59 noncoding region of the HCV genome was
amplified by nested reverse transcription PCR with two sets of universal biotin-
ylated HCV primers. The amplified products were then hybridized to oligonu-
cleotide probes designed to be specific for the different HCV types and subtypes
and were immobilized as parallel bands on nitrocellulose strips (23). The LiPA
procedure was slightly adapted in our laboratory, as described recently (18). The
version of the INNO-LiPA HCV assay used in this work allowed us to identify
HCV genotypes 1a, 1b, 2, 3, and 4 or 5, with the last two not being distinguished
by the assay.
SA1-3. The commercially available assay SA1-3 (Murex Diagnostics) was used
for serotyping. In this assay, eight NS4-encoded genotype-specific branched
peptides are used: three are specific for type 1, three are specific for type 2, and
two are specific for type 3. Each determination needs six different microwells,
including a blank well (no peptide is coated), a no-competition well (all peptides
are coated and no competing peptides are added), an all-competition well (all
peptides are coated and the eight free peptides are added for competition), and
wells that are specific for type 1, type 2, and type 3 (all peptides are coated and
free peptides specific for the types not sought for in the well are added) (Fig. 1).
For example, detection of genotype-specific antibody to type 1 is achieved by the
addition of a 100-fold molar excess of peptides from genotypes 2 and 3 to the test
serum or plasma samples.
The assay was carried out according to the manufacturer’s instructions. Briefly,
10 ml of diluted samples was incubated, in the presence of the serotype-specific
competing peptides, with the five microwells coated with type-specific HCV
antigens. The wells were incubated for 1 h at 37°C to allow the serotype-specific
anti-HCV antibodies to bind to the immobilized antigens. Following washing to
remove unbound material, the captured antibodies were incubated with perox-
idase-conjugated monoclonal anti-human immunoglobulin G for 1 h at 37°C.
After removal of excess conjugate, bound enzyme was detected by the addition
of a solution containing 3,39,5,59-tetramethylbenzidine and hydrogen peroxide. A
purple color developed in the wells which contained anti-HCV-reactive samples.
The enzyme reaction was stopped with sulfuric acid to give an orange color which
was read photometrically.
SA1-6. In the SA1-6 assay, 21 NS4-encoded branched peptides specific for
HCV types 1, 2, 3, 4, 5, and 6 were used in eight wells (no blank well). The
procedure was similar to that described above for SA1-3, except that the conju-
gate was incubated for 30 min at 37°C.
FIG. 1. Principles of SA1-3 and example of the results given by the assay for a patient infected with HCV genotype 1. Eight NS4-encoded genotype-specific branched
peptides are used: three are specific for type 1, three are specific for type 2, and two are specific for type 3. Each determination needs six different microwells. For
example, detection of genotype-specific antibody to type 1 is achieved by the addition of a 100-fold molar excess of peptides from genotypes 2 and 3 to the test serum
or plasma samples. Thus, color appears in the no-competition well and in the specific type 1 well, while no color is visible in the other wells.
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RESULTS
Distribution of HCV genotypes. All 88 serum samples tested
in this study were HCV RNA positive by PCR and could thus
be genotyped by the INNO-LiPA HCV. The distribution of
HCV genotypes, as determined by this assay, was as follows: 19
patients (22%) were infected with HCV type 1a, 34 (39%)
were infected with type 1b, 8 (9%) were infected with type 2, 18
(20%) were infected with type 3, and 9 (10%) were infected
with type 4-5.
Serotyping by SA1-3. The results of SA1-3 are presented in
Table 1 according to the genotype determined by the INNO-
LiPA HCV. Samples from 22 patients (25%) were nonreactive
in the assay; i.e., no antibodies to the NS4-encoded region
where the HCV peptides were designed could be detected. The
sensitivity of the assay was thus 75%. As indicated in Table 1,
the lack of reactivity in the assay was not associated with a
particular genotype. Among the 66 patients who could be se-
rotyped by SA1-3, SA1-3 and the genotyping method gave
concordant results for 61 (92%). However, for sera from five
patients that were reactive only with the type 3 probes in the
INNO-LiPA HCV, SA1-3 was reactive both in the type 1 and
in the type 3 wells, suggesting either mixed type 1 and 3 infec-
tion not detected by the genotyping assay or type 1 and 3
cross-reactivities. Discrepant results were observed for five pa-
tients (8%). The corresponding five samples reacted with the
genotype 4-5 probes in the INNO-LiPA HCV, but with type 1
peptides in SA1-3.
Serotyping by SA1-6. The results of SA1-6 are presented in
Table 1 according to the genotype determined by the INNO-
LiPA HCV. Sera from six patients (7%) were nonreactive in
this assay. In four additional serum samples (4%), including
two that had been serotyped by SA1-3, antibodies were de-
tected but reactivities were non-type specific. This means that
the sample was positive in the no-competition well, but had no
reactivity in any other well (Fig. 1). As indicated in Table 1,
neither the lack of reactivity nor the lack of specificity of the
reactivities was associated with a particular genotype, but no
type 1a sample was found to be nonreactive or non-type spe-
cific in the assay. The overall sensitivity of SA1-6 was 89% for
the study population. Among the 78 patients who could be
serotyped by SA1-6, SA1-6 and the genotyping assay gave
concordant results for 73 (94%). However, two samples that
hybridized only with type 3 probes reacted with both type 1 and
type 3 peptides in SA1-6 (including one sample in which types
1 and 3 were found and one sample in which type 3 alone was
found by SA1-3). Discrepant results between SA1-6 and
INNO-LiPA HCV were observed for samples from five pa-
tients (6%). They included two patients infected with genotype
3 and one patient infected with genotype 4-5 found to be
serotype 1 by SA1-6 and two patients infected with genotype 1b
found to be serotype 4 by SA1-6.
Concordance between the two serotyping assays. Table 2
gives the correspondence between the results of the two suc-
cessive versions of the serotyping assay for the same sera.
Eighty-four percent of the samples found to be positive by both
serotyping assays gave concordant results. Sera from 8 of the
22 patients nonreactive by SA1-3 were nonreactive (six pa-
tients) or non-type specific (two patients) by SA1-6. SA1-6
resolved the results for four of five patients found by SA1-3 to
be infected with types 1 and 3, indicating that they were in-
fected with type 3 alone, whereas the result for one patient
remained type 1 and 3. One additional sample that reacted
only with type 3 probes in the INNO-LiPA HCV and with type
3 peptides in SA1-3 reacted with both type 1 and type 3 pep-
tides in SA1-6, suggesting either mixed infection or type 1 and
3 cross-reactivity. SA1-6 discriminated between type 1 and type
4-5 better than SA1-3 did, because among the five samples that
hybridized with the type 4-5 probes and that reacted with the
type 1 peptides in SA1-3, three reacted with the type 4 peptides
and one reacted with the type 5 peptides in SA1-6. One sample
still reacted with the type 1 peptides, and isolates from the four
patients infected with genotype 4-5 that were nonreactive by
SA1-3 were still not typeable by SA1-6. Twelve samples found
to be nonreactive by SA1-3 were type 1 by SA1-6, suggesting
better sensitivity of SA1-6 for type 1, whereas one type 1
TABLE 1. Results of serotyping by SA1-3 and SA1-6 compared
with genotyping by INNO-LiPA HCV for sera from 88 patients with
chronic hepatitis C eligible for interferon therapy
Assay and
serotype
No. of patients infected with the following HCV genotype, as
determined by INNO-LiPA HCV:
1a (n 5 19) 1b (n 5 34) 2 (n 5 8) 3 (n 5 18) 4-5 (n 5 9)
SA1-3
1 16 24 5
2 7
3 9
1 and 3 5
NRa 3 10 1 4 4
SA1-6
1 19 30 2 1
2 7
3 11
4 2 3
5 1
1 and 3 2
NR 1 2 3
NTSb 1 1 1 1
a NR, nonreactive.
b NTS, non-type specific.
TABLE 2. Concordance of the results of the two serotyping assays (SA1-3 and SA1-6) for sera from 88 patients with chronic hepatitis C
eligible for interferon therapy
Serotype by
SA1-3
No. of patients infected with the following HCV genotype as determined by SA1-6:
1 (n 5 52) 2 (n 5 7) 3 (n 5 11) 4 (n 5 5) 5 (n 5 1) 1 and 3 (n 5 2) NRa (n 5 6) NTSb (n 5 4)
1 (n 5 45) 40 3 1 1
2 (n 5 7) 7
3 (n 5 9) 7 1 1
1 and 3 (n 5 5) 4 1
NR (n 5 22) 12 2 6 2
a NR, nonreactive.
b NTS, non-type specific.
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sample and one type 3 sample by SA1-3 were antibody positive
but non-type specific by SA1-6.
Resolution of discrepant results. Table 3 gives the results of
the three assays and the results of genotyping by sequence
analysis of the 59 noncoding, core, and NS4 regions for 12 of
the 14 samples with discrepant results between at least two of
the three assays. As indicated in Table 3, sequence analysis
confirmed the results of INNO-LiPA HCV for all samples. In
addition, sequencing allowed for the discrimination of types 4
and 5 in those samples identified as genotype 4-5 in INNO-
LiPA HCV. In the patients found to be infected with genotype
3a by INNO-LiPA HCV and types 1 and 3 by one or both of
the serotyping assays, sequence analysis confirmed the results
of INNO-LiPA HCV. However, like INNO-LiPA HCV, se-
quence analysis is based on PCR amplification and can over-
look mixed infections in the event that one genotype replicates
at a higher level than the other one.
Sensitivities of the two serotyping assays and concordance
of results with those of the genotyping assay. Since the result
of INNO-LiPA HCV was confirmed by sequence analysis of
three genome regions for all samples with discrepant results,
INNO-LiPA HCV was used as the reference test to determine
the sensitivities and specificities of SA1-3 and SA1-6. The
results are summarized in Table 4. According to the results of
the INNO-LiPA HCV, the sensitivity of SA1-3 was 75, 87, and
78% for the determination of HCV types 1, 2, and 3, respec-
tively. There was a 100% concordance between the results of
SA1-3 and INNO-LiPA HCV in the identification of HCV
types 2 and 3, but the serotyping assay was concordant with
INNO-LiPA HCV for only 80% of the patients identified as
being infected with genotype 1. This was due to mistyping by
SA1-3 of samples hybridizing with type 4-5 probes and reacting
with type 1 peptides, later resolved in SA1-6. Compared to
SA1-3, SA1-6 had an increased sensitivity for the detection of
type 1-specific antibodies (92%), whereas its sensitivity for type
2 and 3 peptides remained essentially unchanged (87 and 72%,
respectively). SA1-6 detected type 4 or 5 antibodies in only
44% of the samples identified by INNO-LiPA HCV as being
infected with type 4 or 5. The assay had better concordance
with INNO-LiPA HCV for patients identified as being infected
with HCV genotype 1 (91%), whereas there was still a 100%
concordance for the identification of HCV types 2 and 3 be-
tween SA1-6 and the genotyping assay. Finally, the results of
SA1-6 and INNO-LiPA HCV were concordant for only 66% of
the samples hybridizing with type 4-5 probes in the genotyping
assay.
DISCUSSION
The reference method for HCV genotype determination is
full-length genomic sequence analysis followed by phylogenetic
analysis for definitive classification. Such a procedure is not
always necessary, and sequence determination of more limited
regions of the genome is used in most cases. However, this
method is time-consuming and not adapted to clinical studies
or large-scale routine use. Several fast typing methods have
been developed, including subtype-specific amplification (13),
restriction fragment length polymorphism analysis of PCR
products (3, 8), and reverse hybridization (23). One of the
main advantages of INNO-LiPA HCV is standardization of the
commercially available assay. The version of INNO-LiPA
HCV used in the present study was shown to be both sensitive
and specific for the identification of HCV genotypes 1 to 5
(23). However, it is conceivable that spontaneous mutations in
the 59 noncoding region of the genome could be responsible
for mistyping in some cases. This was shown to be the case for
8% of the patients infected with HCV genotype 1 (22). In these
samples, subtypes 1a and 1b cross-reacted in the assay, because
their specific probes differed by only one nucleotide, located at
position 299 of the genome (22). However, possible mistyping
of subtypes of type 1 strains did not influence the results of our
study, because the serotyping assays evaluated did not discrim-
TABLE 3. Results of INNO-LiPA HCV, the two serotyping assays, and sequence analysis of the 59 noncoding, core, and NS4 regions of the
HCV genome for 12 samples with discrepant results among at least two of the three assays evaluated
Sample
Typing results Sequencing resultsa
INNO-LiPA HCV SA1-3 SA1-6 59 NCR Core NS4
BO 1b NRb 4 1b PCR (2) 1b
42 4-5 1 4 4 4 4
44 3a 113 113 3a 3 3a
41 4-5 1 4 4a 4a PCR (2)
12 4-5 1 5 5 5 5
61 3a 113 3 3a 3a 3a
24 4-5 1 1 5 5 5
AE 3a 113 3 3a PCR (2) 3a
AJ 3a 113 3 PCR (2) PCR (2) PCR (2)
BF 3a NR 1 3a 3a 3a
34 3a 113 3 3a 3a 3a
60 3a NR 1 3a 3a 3a
a 59 NCR, 59 noncoding region; PCR (2), PCR negative.
b NR, nonreactive.
TABLE 4. Sensitivity and concordance with molecular biology-
based genotyping of two serotyping assays (SA1-3 and SA1-6) for
identification of HCV genotypes 1 through 5 in 88 patients with
chronic hepatitis C eligible for interferon therapy
Assay and
genotype Sensitivity (%) % Concordance
SA1-3
1 75 80
2 87 100
3 78 100
SA1-6
1 92 91
2 87 100
3 72 100
4-5 44 67
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inate between subtypes 1a and 1b. Overall, INNO-LiPA HCV
could be considered a suitable test for comparison in this study
due to its sensitivity and specificity in the recognition of HCV
types 1, 2, 3, and 4-5. Its accuracy was indeed confirmed in this
work by sequence analysis of three viral genomic regions in
samples with discrepant serotyping assay results, the results of
which always confirmed those of INNO-LiPA HCV.
The formats of the two versions of the Murex Anti-HCV
Serotyping Assay investigated in this study (SA1-3 and SA1-6)
differed considerably from those of previously described sero-
typing assays, which were based on the coating with different
antigens corresponding to different genotypes of different wells
or of nitrocellulose strips (4, 10, 25, 26). Indeed, all wells were
coated with peptides from all studied genotypes. Type-specific
antibody was detected by competition between the solid-phase
antigens and a 100-fold molar excess of peptides added in
solution with the plasma or serum sample (21). This method
guarantees that only those antibodies that can bind to the solid
phase are those that do not cross-react with genotypes heter-
ologous to HCV. In addition, the practicability of the assays
and their easy use by people routinely performing enzyme
immunoassays make them good candidates for use for routine
genotype (serotype) determination.
Our results showed that the results of the first-generation
serotyping assay (SA1-3) were always concordant with those of
the genotyping assay in identifying HCV genotypes 2 and 3. Its
major disadvantages were (i) an overall lack of sensitivity
(75%) that ranged from 75 to 87% according to HCV geno-
type; (ii) a lack of specificity in the detection of type 1-specific
antibodies, due to type 1 reactivities in serum samples that
otherwise hybridized with type 4-5 probes in INNO-LiPA
HCV; and (iii) frequent results indicating mixed type 1 and
type 3 infections. The latter finding was, however, difficult to
interpret because it could be due either to type 1 and type 3
cross-reactivities or to mixed infections with HCV types 1 and
3 not recognized by molecular biology-based genotyping meth-
ods. Molecular biology-based methods often fail to identify
mixed infections because one strain usually becomes predom-
inant and is the only one detected by PCR, an exponential
amplification technique (12). It must be stressed, however, that
mixed infections with distinct HCV genotypes are probably
rare because HCV genotype is strongly related to the source of
infection (18), so that patients are likely most often reinfected
through the same route (e.g., multiple transfusions and intra-
venous drug use) with heterologous strains belonging to the
same genotype. In the absence of a molecular biology-based
test that could be used as a “gold standard,” stating whether
type 1 and 3 infections by SA1-3 were really mixed infections or
related to type 1 and type 3 cross-reactivities was thus difficult.
However, the fact that results for four of these patients were
resolved as type 3 and the results for only one remained type
1 and type 3 in the more specific SA1-6 strongly suggested
unexpected type 1 and type 3 cross-reactivities in SA1-3 that
were avoided in SA1-6. The lack of discrimination between
subtypes 1a and 1b could also be considered a disadvantage of
the SA1-3 because type 1a infects 25 to 60% of the patients
infected with HCV type 1 in the United States and Western
Europe (6, 7, 18). However, recent findings suggested that
HCV types 1a and 1b, although often transmitted through
different routes, were not different with regard to their role in
the pathogenesis of the disease and the sensitivity to interferon
alfa therapy (15). This suggests that subtyping might be useless
if genotype determination is routinely used to tailor treatment
schedules.
The second-generation serotyping assay (SA1-6) was aimed
(i) at improving the sensitivity and the specificity of the sero-
typing assay and (ii) at providing identification of HCV geno-
types 4, 5, and 6. The latter was justified by the fact that HCV
genotype 4 is present in 5 to 10% of the patients with chronic
hepatitis C in Western Europe and that type 5 can also be
encountered in industrialized countries, although it is mostly
present in the South African Republic (3, 18). In contrast, type
6 appears to be limited to Hong Kong, Macao, and Vietnam
(9). Preliminary results obtained with a precommercial version
of SA1-6 did not suggest significant improvement in sensitivity
compared to that of SA1-3 with the 21 genotype-specific HCV
peptides initially included in the assay (14). In the last year, the
sequences used for the peptides have been modified to address
some of the problems associated with reduced sensitivity and
specificity. In addition, sophisticated and effective methods
have been used to coat the ELISA plates with peptides, and the
composition of competing solutions has been changed in the
commercially available version of the ELISA. Overall, our
results suggest improved sensitivity and specificity in the de-
finitive commercially available version of SA1-6 compared to
those of SA1-3. Identification of HCV types 4 and 5 could be
achieved (no sera from a patient infected with type 6 was
included in the study), although both the sensitivities and the
specificities of type 4 and 5 peptides appeared to need further
improvement. The main improvement in SA1-6 was increased
sensitivity and specificity of type 1 antibody detection. Im-
proved specificity for type 1 determination mainly resulted
from the lack of cross-reactivities with samples identified as
type 4-5 by genotyping, and this could mostly be due to the
introduction in the assay of peptides competing with type 4.
The fact that five patients were identified as being infected with
types 1 and 3 by SA1-3, but four were found to be infected only
with type 3 by SA1-6, also suggested better specificity for the
type 1 peptides by SA1-6. In contrast, there was no improve-
ment in the sensitivity of the assay for HCV genotypes 2 and 3,
whereas the concordance of the results with those of the geno-
typing assay in identifying these types remained excellent. Pos-
sible cross-reactivities could still be observed, although at a low
rate. They were mainly found with type 1 and type 4 peptides.
However, two patients were found to be infected with types 1
and 3 by SA1-6, and in these two patients, neither cross-reac-
tivities nor mixed infections could be ruled out. The discrep-
ancies between the two serotyping assays in the diagnosis of
mixed infections questions, however, their real abilities to iden-
tify such cases in the population studied. Finally, in SA1-6,
determination of subtypes 1a and 1b was no more possible than
in SA1-3, but because these two subtypes do not appear to be
pathogenetically different, subtyping might not be absolutely
necessary. Overall, due to the concordance between SA1-6 and
INNO-LiPA HCV for sera from patients such as those studied
here, i.e., patients with chronic hepatitis C eligible for inter-
feron therapy, SA1-6 could routinely be used as an alternative
to molecular biology-based methods for determining HCV ge-
notype so that this information can be used as a tool to tailor
treatment schedules. However, in about 10% of the patients, a
molecular biology-based typing method will be required be-
cause of the lack of sensitivity of the assay in its present form.
In conclusion, the recently commercialized SA1-6 had in-
creased overall sensitivity compared to that of SA1-3 for sera
from unselected patients eligible for interferon therapy, mainly
because of the increased sensitivity of HCV genotype 1-specific
antibody detection. It remained, however, less sensitive than a
standardized genotyping assay based on PCR amplification of
HCV RNA. Both versions of the assay had good concordance
with the genotyping assay, but cross-reactivities between dif-
ferent HCV genotypes could be responsible for mistyping for 8
(SA1-3) and 6% (SA1-6) of the patients. Finally, subtyping of
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types 1a and 1b is still not possible with the existing peptides.
For that reason, serotyping cannot reliably be used for epide-
miological studies. However, it could routinely be used in the
future to tailor treatment schedules according to the infecting
HCV genotype, because discriminating between subtypes does
not appear to be necessary in this setting.
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